首页 Prothena Corp PLC(usPRTA)-基本信息

Prothena Corp PLC(usPRTA)-基本信息

日报更新时间:

周报更新时间:01-09 11:34

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

英文名称:Prothena Corp PLC


简介:Prothena Corporation plc是一家生物技术公司,致力于新型抗体的发现和发展,这些抗体各类疾病的潜在治疗,如蛋白质错误折叠或细胞粘附性疾病


电话:353-1-2362500


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Prothena Corporation plc是一家临床阶段生技公司,专注于新型抗体的发现、开发与商业化,用于治疗各种蛋白错误折叠或细胞黏着的相关疾病,主要针对疾病引起的蛋白质,研发治疗性单株抗体药物。候选产品包括: NEOD001——用于治疗AL淀粉样变性症的单克隆抗体,目前处于III期临床试验阶段; PRX002——已经完成了治疗帕金森病和其他相关突触核蛋白病的Ib期临床试验; PRX003——是一种用于治疗牛皮癣和其他炎性疾病的单克隆抗体,目前处于Ib临床试验阶段; PRX004——是一种单克隆抗体,目前处于临床前发展阶段。Prothena Corporation与F. Hoffmann-La Roche Ltd和Hoffmann-La Roche Inc.签署了许可、开发和商业化协议,以开发和商业化靶向α-突触核蛋白抗体。

交易日期 交易人 职位 类型 交易份额 价格
2017-10-01 Selkoe (Dennis J) Director Sell 201 64.77
2017-10-01 Selkoe (Dennis J) Director Sell 3299 64.13
2017-10-01 Selkoe (Dennis J) Director Buy 3500 16.42
2017-09-27 Henney (Christopher S) Director Sell 900 70.00
2017-09-27 Zago (Wagner M) Officer Sell 900 70.00
2017-09-27 Walker Karin L Officer Sell 1500 70.00
2017-09-27 Walker Karin L Officer Buy 1500 27.81
2017-09-27 Zago (Wagner M) Officer Buy 900 6.41
2017-09-27 Nickerson (Tara) Officer Sell 12776 69.20
2017-09-27 Henney (Christopher S) Director Buy 900 6.65
2017-09-27 Nickerson (Tara) Officer Buy 12776 6.73
2017-09-27 Kinney (Gene G Ph.D.) Chief Executive Officer Sell 2800 70.00
2017-09-27 Kinney (Gene G Ph.D.) Chief Executive Officer Buy 2800 6.41
2017-09-26 Nickerson (Tara) Officer Sell 4724 69.05
2017-09-26 Nickerson (Tara) Officer Buy 4724 6.73
2017-09-24 Nickerson (Tara) Officer Sell 3783 64.33
2017-09-24 Nickerson (Tara) Officer Sell 13717 63.39
2017-09-24 Nickerson (Tara) Officer Buy 17500 6.41

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Morgan Stanley - Brokerage Accounts 681465 1.71% 581519 581.83% 2019-03-31
BlackRock Fund Advisors 2083916 5.23% 1623 0.08% 2019-07-31
Orbimed Advisors, LLC 2435278 6.11% 2435278 -- 2019-03-31
Fidelity Management & Research Company 2733136 6.86% -376326 -12.10% 2019-07-31
BlackRock Inc 3334289 8.36% -20365 -0.61% 2019-03-31
FMR Inc 4187033 10.50% -723397 -14.73% 2019-03-31
Fidelity Management and Research Company 4187033 10.50% -723397 -14.73% 2019-03-31
Woodford Investment Management Ltd 10303198 25.85% -- -- 2019-07-31
Woodford Investment Management LLP 11924614 29.91% -- -- 2019-03-31
Dimensional Fund Advisors, Inc. 1683359 4.22% 410527 32.25% 2019-03-31
State Street Corporation 1521800 3.82% -1371 -0.09% 2019-03-31
Citadel Advisors Llc 1452753 3.64% 255589 21.35% 2019-03-31
EcoR1 Capital, LLC 726519 1.82% -111700 -13.33% 2019-03-31
Fidelity SelectCo, LLC 785454 1.97% -597725 -43.21% 2019-07-31
Northern Trust Investments Inc 793154 1.99% 40352 5.36% 2019-07-31
Vanguard Group Inc 807559 2.03% 113902 16.42% 2019-03-31
Fidelity Management Trust Co 1066101 2.67% -- -- 2019-07-31
Palo Alto Investors, LLC 1108510 2.78% -- -- 2019-03-31
Wellington Management Company LLP 1196828 3.00% -941959 -44.04% 2019-03-31
Dimensional Fund Advisors LP 1435105 3.60% 28468 2.02% 2019-07-31
BlackRock Asset Management Canada Ltd 923704 2.32% -30 -- 2019-05-31
SSGA Funds Management Inc 737785 1.85% -- -- 2019-05-31
Geode Capital Management, LLC 985616 2.47% 542762 122.56% 2018-12-31
Scopia Management Inc 4618164 11.58% 701757 17.92% 2018-12-31
HAP Trading, LLC 654947 1.64% 298892 83.95% 2018-12-31
Bank of America Corporation 529262 1.33% -343695 -39.37% 2018-12-31
Northern Trust Investments N A 495260 1.24% 36018 7.84% 2018-09-30
Northern Trust Corp 495260 1.24% 36018 7.84% 2018-09-30
Millennium Management LLC 738025 1.85% -104139 -12.37% 2018-09-30
T. Rowe Price Associates, Inc. 465273 1.17% -332981 -41.71% 2018-09-30
BlackRock Institutional Trust Company NA 1079111 2.71% 29618 2.82% 2018-06-30
Deerfield Management Co 628262 1.58% 628262 -- 2018-06-30
Morgan Stanley & Co Inc 308007 -- 222635 260.78% 2018-06-30
Pictet Asset Management Ltd 92808 -- 8627 10.25% 2017-09-30
Sectoral Asset Management Inc 216583 -- -25451 -10.52% 2017-09-30
State Street Corp 3421473 -- 1674378 95.84% 2018-06-30
Woodford Patient Capital Trust PLC 2550408 -- 2550408 -- 2017-12-31
Marshall Wace North America LP 199129 -- 199129 -- 2018-03-31
Pinnacle Associates Inc 320874 -- -18990 -5.59% 2018-03-31
ClearBridge, LLC 273420 -- 273420 -- 2018-03-31
Goldman, Sachs & Co. 204372 -- 54280 36.16% 2018-03-31
AllianceBernstein LP 1206516 -- 56200 4.89% 2018-03-31
Camber Capital Management LLC 250000 -- 125000 100.00% 2018-03-31
Westfield Capital Management Company, LP 309819 -- -370840 -54.48% 2018-03-31
Rock Springs Capital Management LP 318500 -- 8500 2.74% 2018-03-31
Bellevue Asset Management AG 433638 -- 49954 13.02% 2018-03-31
NORGES BANK 348016 -- -11410 -3.17% 2017-12-31
Jennison Associates LLC 416031 -- 5313 1.29% 2017-12-31
Capital World Investors 1168214 -- -154900 -11.71% 2017-12-31
ING Investment Management LLC 258106 -- 16559 6.86% 2017-09-30
PointState Capital LP 352400 -- 79900 29.32% 2017-09-30
Putnam Investment Management,LLC 259387 0.67% 259387 -- 2017-09-30
Loomis Sayles & Company LP 334381 0.87% -533 -0.16% 2017-09-30
Vanguard Specialized Funds 2150294 5.59% -- -- 2017-12-31
Oak Ridge Investments, LLC 287656 0.75% -117720 -29.04% 2017-09-30
Wells Capital Management Inc. 359488 1.04% -17908 -4.75% 2016-09-30
Redmile Group, LLC 701659 2.04% 214253 43.96% 2016-09-30
Vanguard Specialized Funds-Vanguard Health Care Fund 1662794 3.00% 48470445 0.10% 1999-11-30
BlackRock, Inc 1674416 3.00% 48809226 0.10% 1999-11-30
Wellington Management Group LLP 2509042 3.00% 73138574 0.10% 1999-11-30
T. Rowe Price Associates, Inc 3436496 3.00% 100173858 0.10% 1999-11-30
FMR LLC 4107618 3.00% 119737065 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
State Street Russell Small/Mid Cap 179386 0.45% -- -- 2019-06-30
LF Woodford Equity Income Fund 7948790 19.94% -- -- 2019-04-30
Woodford Patient Capital Trust 2354408 5.91% -- -- 2019-04-30
Fidelity Growth Company Commingled Pool 1066101 2.67% -- -- 2019-06-30
Worldwide Healthcare 1027000 2.58% 67000 6.98% 2019-04-30
iShares Russell 2000 ETF 884517 2.22% 1727 0.20% 2019-07-30
LF Woodford Income Focus Fund 705000 1.77% -- -- 2019-04-30
Vanguard Extended Market Index Fund 565834 1.42% 2560 0.45% 2019-06-30
SPDR 557058 1.40% 10906 2.00% 2019-07-31
DFA US Small Cap Portfolio 441620 1.11% -- -- 2019-05-31
iShares Nasdaq Biotechnology ETF 390337 0.98% -1160 -0.30% 2019-07-30
iShares Russell 2000 Value ETF 364095 0.91% 738 0.20% 2019-07-31
DFA US Micro Cap Portfolio 289133 0.73% 13622 4.94% 2019-05-31
DFA US Targeted Value Portfolio 277693 0.70% 17190 6.60% 2019-05-31
Wellington Global Health Care Equity 261922 0.66% 3570 1.38% 2019-03-31
Fidelity 192123 0.48% -- -- 2019-06-30
Pictet-Biotech 324454 0.81% -1340 -0.41% 2018-09-30
iShares US Small Cap ETF (CAD-Hedged) 802568 2.01% -1350 -0.17% 2019-05-30
Vanguard Health Care Fund 920628 2.31% -1229666 -57.19% 2018-12-31
Wellington Global Healthcare Equity Fund 260972 0.65% -6575 -2.46% 2018-12-31
iShares Russell 2000 Growth ETF 298945 0.75% 516 0.17% 2018-06-21
Fidelity Advisor 166900 0.42% -- -- 2018-12-31
T. Rowe Price Health Sciences Fund 369849 0.93% -273326 -42.50% 2018-09-30
Quilter Investors UK Equity Income II Fd 281342 0.71% -- -- 2018-09-30
BB Biotech AG 400000 1.00% 50000 14.29% 2018-03-31
T. Rowe Price Instl Small-Cap Stock Fund 504281 1.27% 40300 8.69% 2018-03-31
T. Rowe Price New Horizons Fund 1101650 2.76% -153300 -12.22% 2018-03-31
T. Rowe Price Small-Cap Stock Fund 1068698 2.68% 27400 2.63% 2018-03-31
Vanguard VIF Small Co Gr 105062 0.26% 105062 -- 2018-06-30
iShares Russell 2000 Value 372615 0.85% -- -- 2018-09-12
DFA US Small Cap I 252333 0.63% 29265 13.12% 2018-07-31
Vanguard Explorer Inv 224976 0.56% 224976 -- 2018-06-30
Fidelity VIP Growth Inv 203300 0.51% -- -- 2018-07-31
Fidelity Spartan 195755 0.49% -- -- 2018-07-31
DFA US Targeted Value I 162318 0.41% -- -- 2018-07-31
Mutual of America Small Cap Growth 49298 0.12% -- -- 2018-03-31
iShares Nasdaq Biotechnology 453079 1.04% -861 -0.19% 2018-09-12
State Street Russell Small/Mid Cap Idx Fd Cl I 129860 0.34% 15254 13.31% 2017-06-30
Vanguard Extended Market Idx Inv 523527 1.31% 12815 2.51% 2018-07-31
T. Rowe Price Health Sciences 643175 1.61% -669426 -51.00% 2018-06-30
Vanguard Health Care Inv 2150294 5.40% -- -- 2018-06-30
Schwab US Small-Cap ETF 106787 0.27% -- -- 2018-09-05
Ohio National ClearBridge Small Cap 50880 0.13% 50880 -- 2018-03-31
iShares Micro-Cap 105624 0.26% -- -- 2018-08-09
Metropolitan Ser T. Rowe Price Sm Cp B 39987 0.10% -- -- 2018-03-31
Oak Ridge Small Cap Growth A 63000 0.16% -57000 -47.50% 2018-02-28
Voya SmallCap Opportunities A 118910 0.30% 9015 8.20% 2018-03-31
T. Rowe Price Health Sciences Port II 79041 0.20% -12501 -13.66% 2018-03-31
Harbor Small Cap Growth Instl 104190 0.26% -60150 -36.60% 2018-03-31
T. Rowe Price QM US Small-Cap Growth Eq 205400 0.52% 3100 1.53% 2018-03-31
T. Rowe Price Instl Small-Cap Stock 504281 1.27% 40300 8.69% 2018-03-31
T. Rowe Price Small-Cap Stock 1068698 2.68% 27400 2.63% 2018-03-31
T. Rowe Price New Horizons 1101650 2.77% -153300 -12.22% 2018-03-31
VA CollegeAmerica Smcap World 529E 152000 0.38% -1016214 -86.99% 2018-03-31
iShares Russell 2000 Growth 298945 0.84% 516 0.17% 2018-06-21
AXA/AB Small Cap Growth IB 131520 0.33% -2630 -1.96% 2018-03-31
CREF Stock R1 87322 0.22% 1733 2.02% 2018-03-31
Eventide Healthcare & Life Sciences A 120000 0.31% -- -- 2017-12-31
AB Small Cap Growth A 164360 0.41% -6690 -3.91% 2018-03-31
RI CBF AllianceBern Discovery Gr RA 233900 0.59% -5930 -2.47% 2018-03-31
Prudential Jennison Health Sciences A 179460 0.47% -213396 -54.32% 2018-03-31
Invesco Global Health Care A 168684 0.44% -- -- 2017-12-31
Putnam Multi-Cap Growth A 125600 0.33% 125600 -- 2017-09-30
Oppenheimer International Small-Mid Co A 166170 0.43% -- -- 2017-10-31
Wells Fargo Discovery Admin 180068 0.52% -5400 -2.91% 2016-12-31
Fidelity® Growth Company Fund 2046670 6.50% -22400 -1.10% 2015-09-30
VA CollegeAmerica Small Cap World 1223114 3.90% -- -- 2015-09-30
Fidelity® Select Biotechnology Portfolio 668235 2.10% -- -- 2015-09-30
Fidelity® Series Growth Company Fund 561728 1.80% -- -- 2015-09-30
iShares Russell 2000 (AU) 495924 2.10% -624 -0.10% 2015-11-19
SPDR® S&P Biotech ETF 394745 1.70% 2572 0.70% 2015-11-19
Prudential Jennison Health Sciences 392856 1.20% -- -- 2015-09-30
Fidelity® Select Health Care Portfolio 335102 1.10% -- -- 2015-09-30
CF Woodford Equity Income 4707130 14.20% 300000 6.80% 2015-09-30

Richard T. Collier Richard T. Collier is on the board of Prothena Corp. Plc. Mr. Collier previously was Senior Vice President & General Counsel for Rhone-Poulenc Rorer, Inc., Senior Vice President & General Counsel at Pharmacia Corp., Senior Vice President & General Counsel for Rhone-Poulenc Rorer Pharmaceuticals, Inc., Senior Vice President & General Counsel of Pharmacia & Upjohn Co. LLC and Executive Vice President & General Counsel for Elan Corp. Plc. Richard T. Collier received a graduate degree and an undergraduate degree from Temple University (Pennsylvania).
Dennis J. Selkoe in key research and development roles in other biotechnology companies. Dennis J. Selkoe, M.D., is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and co-director of the Center for Neurologic Diseases at Brigham and Women's Hospital in Boston, positions he has held since 2000 and 1985, respectively. He has served on the faculty at Harvard Medical School since 1978. Dr. Selkoe was the principal founding scientist and served as a director of Athena Neurosciences, Inc. until it was acquired by Elan Corporation, plc in 1996. He has received numerous honors, including the Mathilde Solowey Award in the Neurosciences (NIH), the Potamkin Prize (American Academy of Neurology), the A.H. Heineken Prize for Medicine (The Netherlands), the Pioneer Award and the Lifetime Achievement Award (Alzheimer's Association), the George C. Cotzias Lecture of the American Academy of Neurology and the Ulysses Medal of University College Dublin. Dr. Selkoe is a Fellow of the American Academy of Neurology and of the American Association for the Advancement of Science, a member of the Institute of Medicine of the National Academies and a director of the Foundation for Neurologic Diseases. He served as a director of Elan from 1996 to 2013. Dr. Selkoe earned his B.A. from Columbia University and his M.D. from the University of Virginia. He has served on our Board since 2013. Age: 73 The Board concluded that Dr. Selkoe should serve as a director given his significant experience as both a research scientist and a practicing clinician, and in particular his deep knowledge of and experience with neurological diseases. The Board also considered his lengthy experience as a director of a global public company in the pharmaceutical/biotechnology industry.
Gene G. Kinney Currently, Gene G. Kinney is President, Chief Executive Officer & Director at Prothena Corp. Plc. In his past career Dr. Kinney was Head-Nonclinical Research at Janssen Alzheimer Immunotherapy, Senior Director-Central Pharmacology at Merck Research Laboratories, Senior Vice President-Pharmacological Sciences at Elan Pharmaceuticals LLC and Assistant Professor at Emory University School of Medicine. He received an undergraduate degree from Bloomsburg University of Pennsylvania and a doctorate and a graduate degree from Florida Atlantic University.
Gene G. Kinney Currently, Gene G. Kinney is President, Chief Executive Officer & Director at Prothena Corp. Plc. In his past career Dr. Kinney was Head-Nonclinical Research at Janssen Alzheimer Immunotherapy, Senior Director-Central Pharmacology at Merck Research Laboratories, Senior Vice President-Pharmacological Sciences at Elan Pharmaceuticals LLC and Assistant Professor at Emory University School of Medicine. He received an undergraduate degree from Bloomsburg University of Pennsylvania and a doctorate and a graduate degree from Florida Atlantic University.
Christopher S. Henney Christopher S. Henney is an entrepreneur and businessperson who founded Immunex Corp., ICOS Corp. and Dendreon Corp. and who has been the head of 6 different companies. Dr. Henney is on the board of Anthera Pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc. and Prothena Corp. Plc. In the past Christopher S. Henney occupied the position of Chairman for Allostera Pharma, Inc., Chairman at SGX Pharmaceuticals, Inc., Chairman of Biomira, Inc., Chairman & Chief Executive Officer at Dendreon Corp., Chairman, President & Chief Executive Officer for Cascadian Therapeutics, Inc., Chairman for Xcyte Therapies, Inc., Director, Executive VP & Scientific Director at ICOS Corp., Vice Chairman & Scientific Director at Immunex Corp., Professor at Fred Hutchinson Cancer Research Center, Professor at The Johns Hopkins University and Professor at the University of Washington. Dr. Henney received a doctorate and an undergraduate degree from the University of Birmingham.
Carol D. Karp Carol D. Karp is Chief Regulatory Officer at Prothena Corp. Plc. Ms. Karp is also on the board of the University of Rochester. In the past she was Officer at VIVUS, Inc., Senior VP-Regulatory Affairs & Compliance at Esperion Therapeutics, Inc., Vice President-Scientific Affairs at Powderject Technologies BV, Vice President & Head-Global Regulatory Affairs at Janssen Alzheimer Immunotherapy and SVP-Regulatory Affairs, Quality & Drug Safety at CV Therapeutics, Inc. She received an undergraduate degree from the University of Rochester and an undergraduate degree from New York University.
Dennis J. Selkoe in key research and development roles in other biotechnology companies. Dennis J. Selkoe, M.D., is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and co-director of the Center for Neurologic Diseases at Brigham and Women's Hospital in Boston, positions he has held since 2000 and 1985, respectively. He has served on the faculty at Harvard Medical School since 1978. Dr. Selkoe was the principal founding scientist and served as a director of Athena Neurosciences, Inc. until it was acquired by Elan Corporation, plc in 1996. He has received numerous honors, including the Mathilde Solowey Award in the Neurosciences (NIH), the Potamkin Prize (American Academy of Neurology), the A.H. Heineken Prize for Medicine (The Netherlands), the Pioneer Award and the Lifetime Achievement Award (Alzheimer's Association), the George C. Cotzias Lecture of the American Academy of Neurology and the Ulysses Medal of University College Dublin. Dr. Selkoe is a Fellow of the American Academy of Neurology and of the American Association for the Advancement of Science, a member of the Institute of Medicine of the National Academies and a director of the Foundation for Neurologic Diseases. He served as a director of Elan from 1996 to 2013. Dr. Selkoe earned his B.A. from Columbia University and his M.D. from the University of Virginia. He has served on our Board since 2013. Age: 73 The Board concluded that Dr. Selkoe should serve as a director given his significant experience as both a research scientist and a practicing clinician, and in particular his deep knowledge of and experience with neurological diseases. The Board also considered his lengthy experience as a director of a global public company in the pharmaceutical/biotechnology industry.
Shane M. Cooke Founder of Pembroke Capital Ltd., Shane M. Cooke is on the board of Alkermes, Inc. and 7 other companies. He previously held the position of President at Alkermes Plc and President for Alkermes Pharma Ireland Ltd. (a subsidiary of Alkermes Plc), Chief Executive Officer at Pembroke Capital Ltd., Executive Director, EVP & Head-Drug Technologies at Elan Corp. Plc and EVP, Chief Financial Officer & Director at Elan Drug Technologies. Mr. Cooke received an undergraduate degree from University College Dublin.
Karl Anders Olof H�0�1¤rfstrand Karl Anders Olof H�0�1¤rfstrand is a businessperson who founded H�0�1¤rfstrand Consulting AG and who has been the head of 7 different companies. Presently, he is Chairman at this company. He is also on the board of Karolinska Development AB and Prothena Corp. Plc. He previously was President & Chief Executive Officer at ADAMA Agriculture BV, Chief Executive Officer at to-BBB technologies BV, Chief Executive Officer for to-BBB Holding BV, Senior Executive Vice President at Serono International SA, Principal at Pharmacia, Inc., President & Chief Executive Officer for ADAMA Agricultural Solutions Ltd., Chief Executive Officer & Director at Horizon Pharma Switzerland GmbH, President & Chief Executive Officer of Humabs BioMed SA, Vice President-Country Operations at Pharmacia AB, Director & Executive Vice President at Pfizer Japan, Inc., Senior Executive Vice President at EMD Serono, Inc. and Vice President-Country Operations at Pharmacia & Upjohn, Inc. Karl Anders Olof H�0�1¤rfstrand received a doctorate from Karolinska Institutet.
Lars G. Ekman Lars G. Ekman, M.D., Ph.D., is Chairman of our Board of Directors, a position he has held since 2012. He is an executive partner at Sofinnova Ventures, Inc. (a venture capital firm), a position he has held since 2008. Dr. Ekman is also Chairman of the Board of Sophiris Bio Inc. (a biopharmaceutical company), where he also served as President from 2011 to 2012. He also is Chairman of the Board of Amarin Corporation plc, serves as a director of Spark Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., served as a director of Ocera Therapeutics, Inc. (from 2009 to 2015) and served as a director of InterMune Inc. (from 2006 to 2014). Dr. Ekman co-founded Cebix Incorporated, where he served as Chief Executive Officer from 2009 to 2012. He was President of Research & Development at Elan Corporation, plc (from 2001 to 2007), where he also served as a director (from 2005 to 2012). From 1997 to 2001, Dr. Ekman was Executive Vice President, Research & Development at Schwarz Pharma AG. Prior to that, he held various senior positions at Pharmacia Corporation. Dr. Ekman is a board-certified surgeon with a Ph.D. in experimental biology, and has held several clinical and academic positions in both the United States and Europe. He earned his Ph.D. and M.D. from the University of Gothenburg, Sweden. Dr. Ekman has served on our Board since 2012. Age: 67
Tran B. Nguyen Tran B. Nguyen occupies the position of Chief Operating & Financial Officer of Prothena Corp. Plc. Mr. Nguyen is also on the board of Sierra Oncology, Inc. and Rain Therapeutics, Inc. In the past Mr. Nguyen was Vice President of Citigroup, Inc. and VP-Healthcare Investment Banking Group at Citigroup Global Markets, Inc. (a subsidiary of Citigroup, Inc.), CFO, SVP & Head-Investor Relations at Somaxon Pharmaceuticals, Inc., CFO, Secretary, Treasurer, CAO & VP-Finance at Metabasis Therapeutics, Inc. and VP-Healthcare Investment Banking Group at Lehman Brothers, Inc. Tran B. Nguyen received an undergraduate degree from Claremont McKenna College and an MBA from UCLA Anderson School of Management.
Randy Fawcett Randy Fawcett holds the position of Head-Finance-FP&A, Treasury & IR at Prothena Corp. Plc.
Sarah Noonberg Dr. Sarah Noonberg is Chief Medical Officer at Prothena Corp. Plc. She is on the Board of Directors at Protagonist Therapeutics, Inc. Dr. Noonberg was previously employed as Vice President-Clinical Development by Medivation, Inc., Director-Clinical Development by Chiron Corp., and Group VP & Head-Global Clinical Development by BioMarin Pharmaceutical, Inc. She received her undergraduate degree from Dartmouth College, a doctorate degree from the University of California, Berkeley and a doctorate degree from The University of California, San Francisco.
Karin L. Walker Currently, Karin L. Walker is Chief Accounting Officer & Controller at Prothena Corp. Plc. She previously held the position of Vice President-Finance & Corporate Controller at Amyris, Inc., Chief Accounting Officer & Vice President-Finance at Affymax, Inc. and Vice President-Finance & Corporate Controller at CV Therapeutics, Inc. Ms. Walker received an undergraduate degree from California State Polytechnic University (Pomona).
Karl Anders Olof H�0�1¤rfstrand Karl Anders Olof H�0�1¤rfstrand is a businessperson who founded H�0�1¤rfstrand Consulting AG and who has been the head of 7 different companies. Presently, he is Chairman at this company. He is also on the board of Karolinska Development AB and Prothena Corp. Plc. He previously was President & Chief Executive Officer at ADAMA Agriculture BV, Chief Executive Officer at to-BBB technologies BV, Chief Executive Officer for to-BBB Holding BV, Senior Executive Vice President at Serono International SA, Principal at Pharmacia, Inc., President & Chief Executive Officer for ADAMA Agricultural Solutions Ltd., Chief Executive Officer & Director at Horizon Pharma Switzerland GmbH, President & Chief Executive Officer of Humabs BioMed SA, Vice President-Country Operations at Pharmacia AB, Director & Executive Vice President at Pfizer Japan, Inc., Senior Executive Vice President at EMD Serono, Inc. and Vice President-Country Operations at Pharmacia & Upjohn, Inc. Karl Anders Olof H�0�1¤rfstrand received a doctorate from Karolinska Institutet.
Karl Anders Olof H�0�1¤rfstrand Karl Anders Olof H�0�1¤rfstrand is a businessperson who founded H�0�1¤rfstrand Consulting AG and who has been the head of 7 different companies. Presently, he is Chairman at this company. He is also on the board of Karolinska Development AB and Prothena Corp. Plc. He previously was President & Chief Executive Officer at ADAMA Agriculture BV, Chief Executive Officer at to-BBB technologies BV, Chief Executive Officer for to-BBB Holding BV, Senior Executive Vice President at Serono International SA, Principal at Pharmacia, Inc., President & Chief Executive Officer for ADAMA Agricultural Solutions Ltd., Chief Executive Officer & Director at Horizon Pharma Switzerland GmbH, President & Chief Executive Officer of Humabs BioMed SA, Vice President-Country Operations at Pharmacia AB, Director & Executive Vice President at Pfizer Japan, Inc., Senior Executive Vice President at EMD Serono, Inc. and Vice President-Country Operations at Pharmacia & Upjohn, Inc. Karl Anders Olof H�0�1¤rfstrand received a doctorate from Karolinska Institutet.
Wagner Zago Wagner Zago is Chief Scientific Officer for Prothena Corp. Plc. He received a graduate degree and a doctorate from the University of Sao Paulo and an undergraduate degree from Universidade Federal De Sao Paulo.
Wagner Zago Wagner Zago is Chief Scientific Officer for Prothena Corp. Plc. He received a graduate degree and a doctorate from the University of Sao Paulo and an undergraduate degree from Universidade Federal De Sao Paulo.
Paula K. Cobb Paula K. Cobb is on the board of Prothena Corp. Plc and NightstaRx Ltd. and Chief Operating Officer at Decibel Therapeutics, Inc. She received an undergraduate degree from Amherst College and an MBA from Harvard Business School.
Randy Fawcett Randy Fawcett holds the position of Head-Finance-FP&A, Treasury & IR at Prothena Corp. Plc.
Michael J. Malecek Paula K. Cobb is on the board of Prothena Corp. Plc and NightstaRx Ltd. and Chief Operating Officer at Decibel Therapeutics, Inc. She received an undergraduate degree from Amherst College and an MBA from Harvard Business School.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐